

## Title:

# “Applied research in glioblastoma – why are we stalling?”

## Abstract:

Despite substantial novel insight into the biology of malignant glioma only little progress has been made in the treatment of these diseases. It has been over a decade that temozolomide, an alkylating agent was shown to improve survival when used early in the disease course. Numerous trials since have focused on the ever same targets and pathways (e.g. EGFR or VEGF), and have failed. And most recently, the focus is on immunotherapy for brain tumors, but is this ‘hype’ justified? Many agents may have failed simply because they do not sufficiently cross the blood-brain barrier, and thus we may have predicted the outcome. Based on example, I will review potential pitfalls when moving novel agents and technologies into clinical trials for brain tumors. This seminar will address key elements for clinical and translational research in glioma.

## Date:

**4<sup>th</sup> July 2018**  
**(Wednesday)**

## Time:

**12:00 PM to 1:00 PM**

## Venue:

**Meeting Rm 7C, Lvl 7**  
**Duke-NUS Medical School**  
**8 College Road, S169857**

(Opposite Singapore General Hospital, Block 6/7)

## Host:

**Sin Tiong ONG, MA, MRCP**  
 Associate Professor  
 Programme in Cancer & Stem Cell Biology  
 Duke-NUS Medical School

**“No registration is required.”**

Any enquiry, please contact:  
 Lilian Poon (Tel: 6601 3779)

## Speaker:



## Roger STUPP, MD

Medical Director, Malnati Brain Tumor Institute  
 Assoc. Director, Lurie Comprehensive Cancer Center  
 Professor, Northwestern University  
 Feinberg School of Medicine  
 Depts. of Neurological Surgery, Neurology & Oncology  
 Northwestern University, Chicago, USA

## Biography:

Prof. Stupp trained in Internal Medicine in Switzerland and in Hematology/Oncology at the University of Chicago. He served for over 17 years in numerous roles as a clinician and researcher at the University of Lausanne, and as the Director of the Department of Oncology at the University Hospital in Zurich, Switzerland. In 2017 he was appointed to Northwestern University in Chicago. Prof. Stupp serves as a member of the Board of Directors and Executive Committee of the European Organisation for Research and Treatment of Cancer (EORTC) since 2006 (President from 2012 – 2017). Prof. Stupp's research focuses on early drug development, the combination of chemo- and radiotherapy, multidisciplinary cancer management, namely in the areas of lung cancer and brain tumors. Roger Stupp is best known for his contributions in landmarks trials establishing temozolomide and, most recently tumor treating fields as the standard of care for glioblastoma.